Pharmaq on Tuesday announced that its Alpha Ject Panga 1 vaccine received an observation license from the Department of Animal Health in Vietnam.
The license allows the Norwegian company to begin vaccinations under close observation by authorities and Pharmaq.
Alpha Ject Panga 1 is administered by injection and provides protection against the bacteria Edwardsiella ictaluri, which causes disease in pangasius.
The company is also entering a new phase in trying to establish a best practice for fish vaccination in Vietnam. Activities include vaccination training and close collaboration with farmers during and after vaccination.
“This is the first ever fish vaccine commercially available in Vietnam and represents a breakthrough to both the Vietnamese seafood industry and to Pharmaq,” said Kjersti Gravningen, Pharmaq Vietnam general director. “Our team is prepared and ready for these challenges. The implementation of vaccination will make difference for the farmers in Vietnam.”
“By the introduction of Alpha Ject Pange 1 we have reached a great milestone in the history of Pharmaq and taken another step to strengthen our presence in the global fish health market. Our activities in Vietnam are an essential part of our strategy in exploring the potential of the Asian aquaculture industry,” said Pharmaq CEO Morten Nordstad.
